Fecal immunochemical testing may reduce colorectal cancer mortality
the ONA take:
Population-based fecal immunochemical testing screening for colorectal cancer demonstrated a significant reduction in colorectal cancer mortality despite a short follow-up time, a new study published online in the journal Cancer has shown.
For the prospective cohort study, over 1.1 million Taiwanese people between the ages of 50 and 69 years underwent fecal immunochemical testing screening between 2004 and 2009. Researchers then compared colorectal cancer-specific mortality for a screened group with an unscreened group.
Results showed that fecal immunochemical testing screening reduced colorectal cancer-specific mortality by 62% with a maximum follow-up of 6 years. After adjustments for a self-selection bias, researchers found that screening reduced cancer-specific morality by 10%.
Although the findings show a significant reduction, this study has had a short follow-up time. Researchers plan to continue following-up this large cohort to assess the long-term effect of fecal immunochemical testing screening.
Fecal immunochemical testing screening for colorectal cancer demonstrated a significant reduction in mortality.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genetic Similarity to BRCA1/BRCA2 Mutations May Impact Treatment Options
- Evidenced-Based Radiation Treatment Tied to Cost Savings in Early Stage Breast Cancer
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|